Methodological considerations in estimating adherence and persistence for a long-acting injectable medication

Journal of Managed Care Pharmacy

Volumn 20, Issue 7, 2014, Pages 756-766

  Campagna, Elizabeth J ^a   Muser, Erik ^b   Parks, Joseph ^d   Morrato, Elaine H ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b Food Science and Human Nutrition   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d MISSOURI INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; LONG ACTING DRUG; NEUROLEPTIC AGENT; PALIPERIDONE; DELAYED RELEASE FORMULATION; ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING INJECTABLE ATYPICAL ANTIPSYCHOTIC AGENT; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; DRUG DOSAGE FORM; FEMALE; HUMAN; INJECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METHODOLOGY; PATIENT COMPLIANCE; PHARMACY; PILL; PRESCRIPTION; SCHIZOPHRENIA; TABLET FORMULATION; UNITED STATES; ADOLESCENT; COHORT ANALYSIS; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; FACTUAL DATABASE; MEDICAID; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA; TIME; YOUNG ADULT; CHI SQUARE TEST; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; HEALTH CARE QUALITY; KRUSKAL WALLIS TEST; MEDICAL PARAMETERS; MEDICATION POSSESSION RATIO; MISSOURI; PROPORTION OF DAYS COVERED; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; MISSOURI; SCHIZOPHRENIA; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84903214658     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.7.756     Document Type: Article

References (31)

1. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-99.
2. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-91.
3. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35.
4. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1):91-99.
5. Sajatovic M, Velligan DI, Weiden PJ, Valenstein MA, Ogedegbe G. Measurement of psychiatric treatment adherence. J Psychosom Res. 2010;69(6):591-99.
6. National Committee for Quality Assurance. HEDIS & Performance Measurement. Available at: http://www.ncqa.org/HEDISQuality Measurement.aspx. Accessed February 25, 2014.
7. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-74.
8. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28(9):1411-24.
9. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449-57.
10. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47.
11. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
12. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. Pharmacy Quality Alliance. Available at: http://ep.yimg.com/ty/cdn/epill/pdcmpr.pdf. Accessed February 25, 2014.
13. Siegel SJ. Extended release drug delivery strategies in psychiatry: theory to practice. Psychiatry (Edgmont). 2005;2(6):22-31.
14. Weiden PJ, Mott T, Curcio N. Recognition and management of neuroleptic noncompliance. In: Shriqui CL, Nasrallah HA, eds. Contemporary Issues in the Treatment of Schizophrenia. Arlington, VA: American Psychiatric Press; 1995:411-34.
15. Kane JM. Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry. 1983;44(6 Pt. 2):3-6.
16. Weiden PJ, Zygmunt A. Medication noncompliance in schizophrenia: part I, assessment. J Prac Psych Behav Health. 1997;3:106-10.
17. Kozma CM, Weiden PJ. Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database. Am Health Drug Benefits. 2009;2(1):31-38.
18. Broder MS, Bates JA, Jing Y, Hebden T, Forbes RA, Chang E. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia. J Med Econ. 2012;15(1):105-11.
19. Samtani MN, Sheehan JJ, Fu DJ, Remmerie B, Sliwa JK, Alphs L. Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. Clin Pharmacol. 2012;4:25-40.
20. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 2nd ed. Washington, DC: American Psychiatric Association; 2009.
21. Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics. 1994;5(6):482-504.
22. Sleath B, Domino ME, Wiley-Exley E, Martin B, Richards S, Carey T. Antidepressant and antipsychotic use and adherence among Medicaid youths: differences by race. Community Ment Health J. 2010;46(3):265-72.
23. Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Janssen Pharmaceuticals. January 9, 2014. Available at: http://www.invegasustenna.com/important-product-information. Accessed February 26, 2014.
24. ABILIFY (aripiprazole) dosing. Bristol-Myers Squibb, Otsuka America Pharmaceutical, Inc. April 2011. Available at: http://www.abilify.com/pdf/dosing-guide.pdf. Accessed February 26, 2014.
25. Kozma CM, Durham M, Durkin M, Dickson M, Howe A. PMH84 validity of administrative claims data for calculating adherence measures for longacting injectable (Lai) antipsychotic therapies. Value Health. 2012;15(4):A97.
26. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-40. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8250.
27. Sikirica V, Pliszka SR, Betts KA, et al. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics. J Manag Care Pharm. 2012;18(9):676-89. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=15872.
28. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705.
29. Steiner JF. Rethinking adherence. Ann Intern Med. 2012;157(8):580-85.
30. Valenstein M, McCarthy JF, Ganoczy D, et al. Assertive community treatment in veterans affairs settings: impact on adherence to antipsychotic medication. Psychiatr Serv. 2013;64(5):445-51.
31. Demyttenaere K, Mesters P, Boulanger B, et al. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. J Affect Disord. 2001;65(3):243-52.